For most of modern medicine, biological data has been built around population averages: what people like you might experience, rather than what you personally will. In this episode, Dr Andree Bates speaks with Ken Clark, co-founder and CEO of Enigma Genetics, about moving from population models to personal intelligence, and what it could mean for patients, pharma and the future of biological data.

Ken shares the personal medical experience that led him into this work. After multiple surgeries and a persistent infection, he found that the data needed to understand what had changed in his own biology simply wasn’t available in a useful way. That sparked the idea of creating a personal biological “version history”, a healthy baseline that can be compared against future changes as science and computation improve.

The conversation explores Enigma Genetics’ vision for an AI that lives within a personal health profile, continuously aggregating genetic data, medical records, imaging, wearables and other health information to help build the most comprehensive picture possible for the individual and their doctor. The goal is not to replace medical judgement, but to give clinicians a richer, more personalised foundation for diagnosis and decision making.

Ken also discusses why consent, identity and data ownership need to be rethought. Instead of medical and genetic data being locked inside institutions, Enigma’s model imagines a system where individuals control access, grant or revoke consent, and become active participants in how their data is used.

The key message is that precision medicine cannot fully mature if it is still built on population-level thinking. To unlock the next stage, biological intelligence may need to become more personal, consented, longitudinal and controlled by the individual.

Topics Covered

Why population models fall short for individual biology
Creating a personal biological “version history”
Personal AI profiles for health data and clinical support
Genetic data, imaging, medical records and wearables
Consent, identity, access control and data ownership

Real world evidence and individual-level consent
Clinical trials, rare disease data and patient participation
The future of personalised biological intelligence

Eularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.

If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.

The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.

Details at eularis.com.

AI platforms and tools solve specific problems. Strategy makes sure you’re solving the right ones, in the right order. If you want help mapping priorities as you evaluate what to roll out next, send me a LinkedIn DM starting with ‘PRIORITIES’ and two lines: what’s already in flight, and the decision you’re trying to make next.

About the Podcast

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

Dr. Andree Bates LinkedIn | Facebook | X

E223: From Population Models to Personal Intelligence: Rethinking Biological Data

AI For Pharma Growth

E223: From Population Models to Personal Intelligence: Rethinking Biological Data